Cairo - Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has acquired an anticoagulant molecule as part of its strategy to scale up its portfolio through purchasing existing molecules with an established market presence.
The deal is Rameda's largest acquisition to date that will enable the company to benefit from a large therapeutic area that reported a three-year CAGR of about 67% between 2017 and 2020, according to a statement on Thursday.
The acquisition will be executed through a co-promotion agreement with the seller, which will be finalised and disclosed in due course.
In 2020, Rameda recorded net profits of EGP 111.51 million, up from EGP 81.67 million a year earlier, including minority shareholders’ rights.
